Leucid Bio

The company's core technology is its proprietary Lateral CAR Platform, which engineers CAR molecules to adopt a more natural, side-by-side biological configuration rather than a traditional linear one. This design aims to enhance the potency, persistence, and durability of the T-cell response while potentially reducing toxicity, addressing key challenges that have limited the efficacy of CAR-T therapies against solid tumors. Leucid Bio's business model centers on the research, clinical development, and eventual commercialization of these advanced cell therapies. The company serves patients with hard-to-treat cancers, particularly solid tumors, that have not responded to previous treatments.

Leucid Bio's lead product candidate is LEU011, an autologous CAR-T therapy targeting NKG2D ligands, which are stress proteins expressed on over 80% of human tumor cells. To improve the therapy's ability to reach tumors, LEU011 is also engineered with the CXCR2 chemokine receptor to enhance cell trafficking and infiltration into the tumor microenvironment. The company initiated the Phase 1 "AERIAL" clinical trial for LEU011 in late 2023 to evaluate its safety and efficacy in patients with various relapsed or refractory solid tumors. The first patient was dosed in May 2025. Headquartered in London with operations at Guy's Hospital, Leucid Bio has secured significant funding, including an £11.5 million Series A round in 2021, to advance its clinical programs.